Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck
By
Health News Daily / Health News Daily Oct. 31, 2011
More Stories / Word Count: 1093 / Article # 111031p1
Executive Summary
In the multi-year buildup to the near simultaneous FDA approval and U.S. launch of competing protease inhibitors for hepatitis C, market analysts typically projected that Vertex Pharmaceuticals' Incivek (telaprevir) would outsell Merck & Co.'s Victrelis (boceprevir) on the basis of better cure rates in clinical trials and shorter duration of therapy for many patients
$50.00
Buy Now
For $50.00, purchase this 1093-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.